MX2018012268A - Receptores de celulas t. - Google Patents
Receptores de celulas t.Info
- Publication number
- MX2018012268A MX2018012268A MX2018012268A MX2018012268A MX2018012268A MX 2018012268 A MX2018012268 A MX 2018012268A MX 2018012268 A MX2018012268 A MX 2018012268A MX 2018012268 A MX2018012268 A MX 2018012268A MX 2018012268 A MX2018012268 A MX 2018012268A
- Authority
- MX
- Mexico
- Prior art keywords
- tcrs
- cells
- cell receptors
- nucleic acids
- mage
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 8
- 210000004027 cell Anatomy 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000011786 HLA-A Antigens Human genes 0.000 abstract 1
- 108010075704 HLA-A Antigens Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención está relacionada con receptores de células T (TCRs) los cuales se unen al péptido restringido de HLA-A'0201 GVYDGEEHSV (SEQ ID NO: 2) derivado de la proteína MAGE-B2. Los TCRs de la invención demuestran excelentes perfiles de especificidad para este epítope de MAGE. También se proporcionan ácidos nucleicos que codifican los TCRs, células diseñadas para presentar los TCRs, células que albergan vectores de expresión que codifican los TCRs y composiciones farmacéuticas que comprenden los TCRs, ácidos nucleicos o células de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606156 | 2016-04-08 | ||
| PCT/EP2017/058578 WO2017174823A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012268A true MX2018012268A (es) | 2019-02-07 |
| MX389173B MX389173B (es) | 2025-03-20 |
Family
ID=58536983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012268A MX389173B (es) | 2016-04-08 | 2017-04-10 | Receptores de celulas t. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190144521A1 (es) |
| EP (2) | EP3440104B2 (es) |
| JP (2) | JP7204484B2 (es) |
| KR (1) | KR20190065189A (es) |
| CN (2) | CN109476724B (es) |
| AU (2) | AU2017248121B2 (es) |
| BR (1) | BR112018070637A2 (es) |
| CA (1) | CA3020555A1 (es) |
| ES (1) | ES2788188T5 (es) |
| IL (1) | IL262124A (es) |
| MX (1) | MX389173B (es) |
| RU (1) | RU2018138837A (es) |
| SG (1) | SG11201808750PA (es) |
| WO (1) | WO2017174823A1 (es) |
| ZA (1) | ZA201806862B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| SG10202102698VA (en) | 2014-12-23 | 2021-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| ES2788188T5 (es) * | 2016-04-08 | 2023-10-24 | Adaptimmune Ltd | Receptores de linfocitos T |
| HUE056433T2 (hu) | 2016-04-08 | 2022-02-28 | Adaptimmune Ltd | T-sejt receptorok |
| DK3440102T3 (da) | 2016-04-08 | 2024-07-22 | Adaptimmune Ltd | T-cellereceptorer |
| KR20200063215A (ko) | 2017-10-06 | 2020-06-04 | 오슬로 유니버시테시케후스 에이치에프 | 키메라 항원 수용체 |
| WO2019151392A1 (ja) * | 2018-01-31 | 2019-08-08 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| WO2019204683A1 (en) * | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| CN110172091B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| AU2020295401A1 (en) * | 2019-06-18 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | MAGE-A4 T cell receptors and methods of use thereof |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| JP2022545643A (ja) | 2019-08-13 | 2022-10-28 | キングス・カレッジ・ロンドン | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| MX2023007519A (es) * | 2020-12-22 | 2023-08-03 | Amgen Inc | Receptores de celulas t especificos de mage-b2. |
| WO2022190009A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| US12161673B2 (en) | 2022-09-14 | 2024-12-10 | Cdr-Life Ag | MAGE-A4 peptide dual T cell engagers |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025021979A1 (en) * | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2025021968A1 (en) * | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) * | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US6710172B1 (en) | 1998-10-02 | 2004-03-23 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| US6407063B1 (en) * | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
| US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| WO2003020763A2 (en) | 2001-08-31 | 2003-03-13 | Avidex Limited | Soluble t cell receptor |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| JPWO2010114129A1 (ja) * | 2009-04-03 | 2012-10-11 | 国立大学法人愛媛大学 | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| EP2440575B1 (en) | 2009-06-09 | 2014-11-05 | Vaxon Biotech | Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy |
| EP3213765B1 (en) | 2010-09-20 | 2019-08-28 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| BR112014008691A2 (pt) * | 2011-10-14 | 2017-06-13 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos para cd1d |
| KR102301464B1 (ko) * | 2013-06-10 | 2021-09-14 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
| JP6255360B2 (ja) * | 2015-03-04 | 2017-12-27 | ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ | 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用 |
| HUE056433T2 (hu) * | 2016-04-08 | 2022-02-28 | Adaptimmune Ltd | T-sejt receptorok |
| DK3440102T3 (da) | 2016-04-08 | 2024-07-22 | Adaptimmune Ltd | T-cellereceptorer |
| ES2788188T5 (es) | 2016-04-08 | 2023-10-24 | Adaptimmune Ltd | Receptores de linfocitos T |
| US11505590B2 (en) * | 2016-04-08 | 2022-11-22 | Immunocore Limited | T cell receptors |
-
2017
- 2017-04-10 ES ES17716871T patent/ES2788188T5/es active Active
- 2017-04-10 CA CA3020555A patent/CA3020555A1/en active Pending
- 2017-04-10 SG SG11201808750PA patent/SG11201808750PA/en unknown
- 2017-04-10 CN CN201780031701.3A patent/CN109476724B/zh active Active
- 2017-04-10 MX MX2018012268A patent/MX389173B/es unknown
- 2017-04-10 EP EP17716871.3A patent/EP3440104B2/en active Active
- 2017-04-10 CN CN202310214446.3A patent/CN116239669A/zh active Pending
- 2017-04-10 EP EP20020115.0A patent/EP3925972A1/en active Pending
- 2017-04-10 KR KR1020187032157A patent/KR20190065189A/ko not_active Ceased
- 2017-04-10 WO PCT/EP2017/058578 patent/WO2017174823A1/en not_active Ceased
- 2017-04-10 RU RU2018138837A patent/RU2018138837A/ru unknown
- 2017-04-10 JP JP2018552775A patent/JP7204484B2/ja active Active
- 2017-04-10 AU AU2017248121A patent/AU2017248121B2/en not_active Ceased
- 2017-04-10 BR BR112018070637A patent/BR112018070637A2/pt not_active Application Discontinuation
-
2018
- 2018-10-04 IL IL262124A patent/IL262124A/en unknown
- 2018-10-08 US US16/154,270 patent/US20190144521A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06862A patent/ZA201806862B/en unknown
-
2021
- 2021-10-14 US US17/501,200 patent/US11753456B2/en active Active
-
2022
- 2022-05-24 JP JP2022084419A patent/JP7572399B2/ja active Active
- 2022-10-20 AU AU2022256182A patent/AU2022256182A1/en not_active Abandoned
-
2023
- 2023-08-01 US US18/363,672 patent/US12180261B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012268A (es) | Receptores de celulas t. | |
| MX2018012265A (es) | Receptores de celulas t. | |
| MX2022011309A (es) | Receptores de celulas t. | |
| MX2017004559A (es) | Receptores de celulas t. | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| NZ715038A (en) | T cell receptors | |
| CL2017002345A1 (es) | Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| PH12014502669A1 (en) | Therapeutic agent or prophylactic agent for dementia | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| EA202191123A1 (ru) | Миниатюризированные дистрофины и их применения | |
| CL2020002373A1 (es) | Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422). | |
| CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
| MX2021014856A (es) | Vacuna de tgf-beta. | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| MX380003B (es) | Péptidos topk y vacunas que incluyen los mismos. | |
| BR112019007343A2 (pt) | sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina | |
| MX2021003441A (es) | Polipeptidos de arginasa1. | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины |